1. What is the recommended treatment approach for DMARD-naive patients with moderate-to-high disease activity in rheumatoid arthritis, according to the 2021 American College of Rheumatology guideline?
2. In patients with subcutaneous nodules and moderate-to-high disease activity, what is the preferred DMARD therapy based on the guideline?
3. For patients with pulmonary disease and moderate-to-high disease activity, what is the recommended DMARD treatment according to the guideline?
4. What is the suggested course of action for patients with heart failure and inadequate response to csDMARDs, as per the guideline?
5. In patients with lymphoproliferative disorder and moderate-to-high disease activity, what is the preferred DMARD therapy based on the guideline?
6. How should healthcare providers manage patients with hepatitis B infection initiating rituximab therapy, as per the guideline?
7. What is the recommended approach for DMARD-naive patients with nonalcoholic fatty liver disease and moderate-to-high disease activity, according to the guideline?
8. In patients with persistent hypogammaglobulinemia without infection, what is the guideline's recommendation regarding rituximab therapy continuation?
9. For patients with a history of serious infection within the previous 12 months and moderate-to-high disease activity, what is the recommended treatment approach according to the guideline?
10. How should healthcare providers manage patients with nontuberculous mycobacterial lung disease and moderate-to-high disease activity despite csDMARD monotherapy, based on the guideline's recommendations?